Luteinizing Hormone (lh) Or Derivative Patents (Class 514/10.1)
-
Patent number: 11376220Abstract: Methods and formulations for a simplified, single-injection method to induce and control the synchronous growth (superstimulation), and ovulation (superovulation) of multiple ovarian follicles in bovine, ovine, caprine, camelid and other female animals enabling the subsequent collection of (a) multiple oocytes when conducting in-vitro fertilization, or (b) multiple embryos when conducting multiple ovulation embryo transfer.Type: GrantFiled: March 5, 2018Date of Patent: July 5, 2022Assignee: THERIO, LLCInventor: John L. Curtis
-
Patent number: 11292824Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises ?2,3- and ?2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using ?2,3-sialyltransferase.Type: GrantFiled: December 10, 2019Date of Patent: April 5, 2022Assignee: FERRING B.V.Inventors: Ian Cottingham, Daniel Plaksin, Richard White
-
Patent number: 10675333Abstract: An infusion pump is disclosed comprising control unit, container, actuation unit and detection unit. The container can store medicinal liquid for treating hypogonadotropic hypogonadism. The control unit can receive external control signal comprising infusion interval, concentration of medicinal liquid and dose of medicament for treating hypogonadotropic hypogonadism at each infusion. The control unit is configured to activate actuation unit based on infusion interval to cause medicinal liquid to flow out of container. The detection unit can detect output of medicinal liquid from container and feed it back to control unit. The control unit is configured to activate actuation unit based on dose at each infusion, concentration of medicinal liquid and fed-back output of medicinal liquid. According to the invention, sustained, automatic infusions of the medicament for treating hypogonadotropic hypogonadism are allowed without patient intervention.Type: GrantFiled: May 31, 2017Date of Patent: June 9, 2020Inventors: Guang Ning, Weiqing Wang, Shouyue Sun
-
Patent number: 10668127Abstract: Methods and compositions for synchronizing the time of insemination in swine are described. More particularly, methods are described for synchronizing the time of insemination by administration of a composition comprising a hormone, wherein the swine is inseminated only one time after administration of the hormone, and wherein there is no heat detection.Type: GrantFiled: July 26, 2017Date of Patent: June 2, 2020Assignee: United-AH II, LLCInventors: Stephen Kent Webel, Mark E. Swanson
-
Patent number: 10376558Abstract: Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided.Type: GrantFiled: July 26, 2017Date of Patent: August 13, 2019Assignee: United-AH II, LLCInventors: Stephen Kent Webel, Mark E. Swanson, Robert R. Kraeling, Michael E. Johnston
-
Patent number: 10111961Abstract: Microparticles and nanoparticles of hydrophobized proteins and an alpha-cyclodextrin, obtained by auto-association in an aqueous medium, the hydrophobized protein being obtained by grafting of alkyl chains coming from fatty acids, by an acylation reaction. These microparticles and nanoparticles constitute systems used for encapsulation of active substances of interest, in particular in the pharmaceutical field, and the vectorization thereof for therapeutic purposes.Type: GrantFiled: May 2, 2014Date of Patent: October 30, 2018Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD XIInventor: Kawthar Bouchemal
-
Patent number: 9993426Abstract: A pharmaceutical composition comprising bisacodyl [4,4?-(pyridine-2-ylmethylene)bis(4,1-phenylene) diacetate], a solvent, a buffer, and a polymer, methods and apparatus for delivery to a patient.Type: GrantFiled: September 7, 2016Date of Patent: June 12, 2018Assignee: C. B. Fleet Company, Inc.Inventors: Nelson P. Ayala, Ping Qiu, Debanjan Das, Dave Zimmerman
-
Patent number: 9644011Abstract: The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.Type: GrantFiled: January 11, 2013Date of Patent: May 9, 2017Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Philippe Favreau, Evelyne Benoit, Jordi Molgo, Reto Stöcklin
-
Patent number: 9204895Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.Type: GrantFiled: December 19, 2014Date of Patent: December 8, 2015Assignee: Palo Alto Research Center IncorporatedInventors: Scott A. Uhland, Ramkumar Abhishek, Eric Peeters, Timothy J. Curley, Felicia Linn
-
Patent number: 8962561Abstract: A method of treating or preventing an ovary-related syndrome associated with infertility in a subject in need thereof is provided. The method comprising administering to the subject a pharmaceutical composition comprising an active ingredient consisting of pigment epithelium-derived factor (PEDF) and a pharmaceutically acceptable carrier, thereby treating or preventing the ovary-related syndrome associated with infertility in the subject.Type: GrantFiled: November 11, 2010Date of Patent: February 24, 2015Assignees: Ramot at Tel-Aviv University Ltd., The Fund for Medical Research, Development of Infrastructure and Health Services—Assaf HaRofeh Medical CenterInventors: Ruth Shalgi, Dana Chuderland, Ido Ben-Ami, Raphael Ronel
-
Publication number: 20140228292Abstract: The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.Type: ApplicationFiled: July 9, 2012Publication date: August 14, 2014Applicant: ARTS BIOLOGICS A/SInventors: Peter Nordkild, Svend Lindenberg, Claus Yding Andersen, Kim Vilbour Andersen
-
Publication number: 20140155327Abstract: A method for synchronizing ovulation in sows and gilts without heat detection by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred without heat detection at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.Type: ApplicationFiled: April 23, 2013Publication date: June 5, 2014Applicant: Thorn BioScience LLCInventor: Thorn BioScience LLC
-
Patent number: 8722088Abstract: Compositions, kits, and methods are provided directed to the treatment of prostate cancer using a maintenance dose of degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent.Type: GrantFiled: April 30, 2010Date of Patent: May 13, 2014Assignee: Ferring International Center S.A.Inventors: Tine Kold Olesen, Lars Erichsen, Per Cantor
-
Patent number: 8709998Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.Type: GrantFiled: April 21, 2004Date of Patent: April 29, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelena Shen, Jeanne Mary Comstock, Sun H. Kim
-
Publication number: 20140088010Abstract: Preparations including poly (ethylene glycol) modified recombinant hCG(rhCG).Type: ApplicationFiled: March 29, 2012Publication date: March 27, 2014Applicant: FERRING B.V.Inventors: Ian Cottingham, Daniel Plaksin, Jenny Aharanov
-
Patent number: 8680055Abstract: The present invention discloses compositions and methods for treating diseases such as cancer by targeting luteinizing hormone (LH) or its receptor (LHR) involved in androgen synthesis or testosterone production.Type: GrantFiled: June 2, 2010Date of Patent: March 25, 2014Assignee: University of Southern CaliforniaInventor: Jacek Pinski
-
Patent number: 8663681Abstract: The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.Type: GrantFiled: May 26, 2006Date of Patent: March 4, 2014Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Charles E. Diliberti, Chandra Vattikonda, Sudhir R. Gorukanti, Sanjeev K. Gupta
-
Patent number: 8664369Abstract: The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.Type: GrantFiled: October 29, 2008Date of Patent: March 4, 2014Assignee: Merck Serono S.A.Inventors: Rita Agostinetto, Fabrizio Samaritani, Alessandra Del Rio, Joel Richard
-
Publication number: 20140050775Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: ApplicationFiled: March 8, 2013Publication date: February 20, 2014Applicant: Egen, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Patent number: 8518890Abstract: A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided.Type: GrantFiled: September 28, 2007Date of Patent: August 27, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahito Hara, Masami Kusaka
-
Patent number: 8470776Abstract: The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.Type: GrantFiled: March 19, 2010Date of Patent: June 25, 2013Assignee: Aeterna Zentaris GmbHInventors: Eckhard Guenther, Olaf Schaefer, Michael Teifel, Klaus Paulini
-
Publication number: 20130116177Abstract: Described herein are methods for synchronizing ovulation in a herd, inducing superovulation in a single animal, and improving frequency of successful implantation and development of fertilized ova.Type: ApplicationFiled: May 19, 2011Publication date: May 9, 2013Applicant: University of SaskatchewanInventors: Roger Pierson, Gregg Adams
-
Patent number: 8435949Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.Type: GrantFiled: June 11, 2012Date of Patent: May 7, 2013Assignee: Stem Cell Therapeutics Corp.Inventors: Samuel Weiss, Emeka Enwere, Linda Andersen, Christopher Gregg
-
Publication number: 20130090288Abstract: The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. Said pharmaceutical compositions contain said at least one protein active ingredient, in free form, as well as, for liquids, a system that buffers them to a pH greater than 4 and less than or equal to 8 or, for solids, a system that exerts, when they are placed a liquid medium, a buffer effect between a pH greater than 4 and a pH less than or equal to 8.Type: ApplicationFiled: November 12, 2012Publication date: April 11, 2013Inventors: Farid Bennis, Jean-Jacques Serrano
-
Patent number: 8372806Abstract: The transdermal delivery system for treating infertility in a patient comprises an apparatus (10) for facilitating transdermal delivery of a drug (5a) through an area of the apparatus (10) comprises an ablator that is configured to generate a microporation in the area of the skin of the patient, and comprises a drug (5a), wherein the drug effects at least one of the biological regulation of at least one oocyte containing follicle, stimulation of follicle growth, induction of ovulation, promotion of gestational status, maintenance of conceptus, maintenance of pregnancy.Type: GrantFiled: October 6, 2006Date of Patent: February 12, 2013Assignee: Pantec Biosolutions AGInventors: Christof Böhler, Thomas Bragagna, Reinhard Braun, Werner Braun, Herbert Zech
-
Publication number: 20130029911Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: September 12, 2012Publication date: January 31, 2013Inventors: Craig A. Rosen, William A. Haseltine
-
Publication number: 20130023476Abstract: Preparations including recombinant hCG (r hCG).Type: ApplicationFiled: October 4, 2010Publication date: January 24, 2013Applicant: FERRING B.V.Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
-
Publication number: 20130017169Abstract: Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo.Type: ApplicationFiled: March 2, 2011Publication date: January 17, 2013Applicant: PROTALIX LTD.Inventors: Ilya Ruderfer, Orit Shilovittzky, Avidor Shulman, Joseph Shaaltiel, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay
-
Patent number: 8343920Abstract: The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage, injury or disease.Type: GrantFiled: June 27, 2011Date of Patent: January 1, 2013Assignee: Stem Cell Therapeutics Corp.Inventor: Joseph Tucker
-
Patent number: 8334258Abstract: The present invention relates to methods for inducing and enhancing apoptosis in pathogenic cells. In particular, the present invention relates to the use of GnRH II antagonists for inducing and enhancing apoptosis of specific types of tumor cells, i.e. breast cancer and malignant melanoma as well as gynaecological cancers like endometrial or ovarian cancer, expressing the GnRH II receptor as well as to methods relating thereto. In addition, new GnRH II antagonists are provided.Type: GrantFiled: July 20, 2006Date of Patent: December 18, 2012Assignee: Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (Universitätsmedizin)Inventors: Carsten Gruendker, Andreas R. Guenthert, Guenter Emons
-
Patent number: 8329863Abstract: Antagonistic peptides of GnRH having improved water solubility are disclosed. These peptides are capable of suppressing serum testosterone levels in vivo to chemical castration levels of ?0.5 ng/ml. Stable, filter sterilizable, non-gelling solutions containing the GnRH antagonists at least at levels typically used in sustained release formulations also are disclosed, as is a method of increasing the solubility of GnRH antagonist in a polymer containing dispersed phase, which method comprises addition of an acid to the dispersed phase.Type: GrantFiled: July 18, 2005Date of Patent: December 11, 2012Assignee: Oakwood Laboratories, LLCInventors: Bagavathikanun C. Thanoo, James Murtagh
-
Publication number: 20120309681Abstract: Methods, compositions and kits for treating or ameliorating the following disorders, in male, with help of prolactin are disclosed: a) erectile dysfunction (ED), also from aging, of pituitary/hypothalamic origin; b) premature ejaculation (PE), of pituitary/hypothalamic origin. Said methods, compositions and kits comprise prolactin, variants, analogs, agonists and functional fragments of prolactin, also in combination with conventional therapies and drugs (eg testosterone/androgens and/or gonadotropins).Type: ApplicationFiled: May 31, 2011Publication date: December 6, 2012Inventor: Mario SARGENTINI
-
Publication number: 20120258176Abstract: The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent.Type: ApplicationFiled: May 7, 2012Publication date: October 11, 2012Inventors: Hsing-Wen Sung, Zi-Xian Liao, Shu-Fen Peng, Hosheng Tu
-
Publication number: 20120245084Abstract: A formulation of a diluted amino acid segment is prepared by mixing an amino acid segment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid segment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation.Type: ApplicationFiled: March 23, 2012Publication date: September 27, 2012Applicant: DESERET BIOLOGICALS, INC.Inventors: Jacob L. Carter, Edwin Douglas Lephart
-
Publication number: 20120244111Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.Type: ApplicationFiled: June 11, 2012Publication date: September 27, 2012Applicant: Stem Cell Therapeutics Corp.Inventors: Samuel WEISS, Emeka ENWERE, Linda ANDERSEN, Christopher GREGG
-
Patent number: 8258100Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.Type: GrantFiled: June 19, 2009Date of Patent: September 4, 2012Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
-
Publication number: 20120195932Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for to later addition of cargo moieties are also contemplated.Type: ApplicationFiled: January 25, 2010Publication date: August 2, 2012Applicant: BioDelivery Sciences International, Inc.Inventors: Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
-
Patent number: 8217002Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.Type: GrantFiled: October 29, 2010Date of Patent: July 10, 2012Assignee: Stem Cell Therapeutics Corp.Inventors: Samuel Weiss, Emeka Enwere, Linda Andersen, Christopher Gregg
-
Publication number: 20120164072Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.Type: ApplicationFiled: May 4, 2010Publication date: June 28, 2012Inventors: Charles Linder, Sarina Grinberg, Eliahu Heldman
-
Publication number: 20120148529Abstract: The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.Type: ApplicationFiled: May 12, 2010Publication date: June 14, 2012Applicants: Centro de Invesigacion Biomedica en Red en Bioiagenieria, Biomateriales, y Nanomedicina (Cibe, Universitat Autonoma de Barcelona et al.Inventors: Elena Garcia-Fruitos, Esther Vazquez Gomez, Jose Luis Corchero, Antonio Pedro Villa Verde Corrales
-
Patent number: 8173770Abstract: The peptides Ac-D-2Nal-D-4ClPhe-D-3Pal-OH and Boc-D-2Nal-D-4ClPhe-D-3Pal-OH are intermediates useful in the synthesis of LHRH analogs by coupling with suitable heptapeptides, in particular with the heptapeptides P1-Ser(P2)-MMeTry(P3)-D-Lys(Nic)-Leu-Lys(iPr,P4)-Pro-D-AlaNH2 and P1-Ser(P2)-NMeTry(P3)-D-Asn-Leu-Lys(iPr,P4)-Pro-D-AlaNH2.Type: GrantFiled: August 12, 2008Date of Patent: May 8, 2012Assignee: Polypeptide Laboratories A/SInventors: Jon H. Rasmussen, Palle H. Rasmussen, Wolfgang O. Wachs, Stefan Hansen, Jens Fomsgaard
-
Patent number: 8173592Abstract: A method of therapeutic management of infertility by programming of controlled ovarian stimulation and assisted reproductive procedures is disclosed containing the steps of a) suppression of premature ovulation with an LHRH-antagonist in controlled ovarian stimulation and assisted reproductive techniques with multiple follicle and oocyte development; b) programming the start of controlled ovarian stimulation by the administration to a patient of progestogen only-preparations or, alternatively, combined oral contraceptive preparations; c) exogenous stimulation of the ovarian follicle growth; d) ovulation induction with HCG, native LHRH, LHRH-agonists or recombinant LH; and e) application of assisted reproduction techniques, especially of IVF, ICSI, GIFT, ZIFT or by intrauterine insemination by sperm injection, wherein onset of the patient's menstrual cycle and of controlled ovarian stimulation are programmed in order to perform oocyte pickup and fertilization procedures during Mondays to Fridays.Type: GrantFiled: March 10, 2000Date of Patent: May 8, 2012Assignee: Zentaris IVF GmbHInventors: Jurgen Engel, Hilde Riethmuller-Winzen
-
Publication number: 20120052077Abstract: The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.Type: ApplicationFiled: January 13, 2010Publication date: March 1, 2012Inventors: Edward R. Truitt, III, Benjamin Sullivan, David Sullivan
-
Publication number: 20120046228Abstract: The present invention relates to methods and reagents for modulating ovulation in humans and non-human animals.Type: ApplicationFiled: August 18, 2011Publication date: February 23, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventor: Carlos A. Molina
-
Publication number: 20120045430Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.Type: ApplicationFiled: August 15, 2011Publication date: February 23, 2012Inventors: Dan Luo, Yougen Li
-
Publication number: 20120040886Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventor: Zheng Xin Dong
-
Publication number: 20120040885Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Publication number: 20110306547Abstract: A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural level S thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day . LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec.Type: ApplicationFiled: November 8, 2010Publication date: December 15, 2011Applicant: Zentaris GmbHInventors: PHILIPPE BOUCHARD, Rene Frydman, Paul Devroey, Klaus Diedrich, Jürgen Engel
-
Publication number: 20110286998Abstract: Methods are provided for treating HPG axis-positive cancers, preventing or slowing proliferation of cells of HPG axis-positive cancer origin, preventing HPG axis-positive cancers in a patient at risk of contracting such cancers, preventing or inhibiting an upregulation of the cell cycle in HPG axis-positive cancer-derived cells in a patient, and decreasing the level of HPG axis-positive cancer-specific markers in a patient.Type: ApplicationFiled: November 19, 2010Publication date: November 24, 2011Applicant: Voyager Pharmaceutical CorporationInventors: Christopher W. Gregory, Maria E. Kononov, Eric S. Werdin, James Lester Barbee, IV, Carol Giamario
-
Publication number: 20110263500Abstract: Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.Type: ApplicationFiled: September 16, 2009Publication date: October 27, 2011Inventors: William Hansel, Sita Aggarwal, Robert P. Hammer